Thai PBS Thai PBS
Thai GPO launches 2nd phase of clinical trials of inactivated chimeric vaccine

Thai GPO launches 2nd phase of clinical trials of inactivated chimeric vaccine

13 Sept 06:37 Key points summarised by AI
  • Thailand’s Government Pharmaceutical Organization (GPO) commenced the second phase of human trials for its HXP-GPOVac COVID-19 vaccine candidate, involving 250 healthy volunteers, following promising immune responses in initial trials.
  • The vaccine's prototype, an inactivated chimeric vaccine, was provided by PATH, a global non-profit health organization, and developed by the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin.
  • GPO expects to register the vaccine under Emergency Use Authorization and begin mass production by mid-next year, aiming for 20-30 million doses annually to enhance Thailand's vaccine security and independence.
Read full article
Thai PBS World 1/1
Skip > Skip >